The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Predictive performance of the competing risk model in screening for preeclampsia
Open accessAbstract
Background: The established method of screening for preeclampsia is to identify risk factors from maternal demographic characteristics and medical history; in the presence of such factors the patient is classified as high risk and in their absence as low risk. However, the performance of such an approach is poor. We developed a competing risks model, which allows combination of maternal factors (age, weight, height, race, parity, personal and family history of preeclampsia, chronic hypertension, diabetes mellitus, systemic lupus erythematosus or antiphospholipid syndrome, method of conception and interpregnancy interval), with biomarkers to estimate the individual patient‐specific risks of preeclampsia requiring delivery before any specified gestation. The performance of this approach is by far superior to that of the risk scoring systems. Objective: The objective of the study was to examine the predictive performance of the competing risks model in screening for preeclampsia by a combination of maternal factors, mean arterial pressure, uterine artery pulsatility index, and serum placental growth factor, referred to as the triple test, in a training data set for the development of the model and 2 validation studies. Study Design: The data for this study were derived from 3 previously reported prospective, nonintervention, multicenter screening studies for preeclampsia in singleton pregnancies at 11+0 to 13+6 weeks’ gestation. In all 3 studies, there was recording of maternal factors and biomarkers and ascertainment of outcome by appropriately trained personnel. The first study of 35,948 women, which was carried out between February 2010 and July 2014, was used to develop the competing risks model for prediction of preeclampsia and is therefore considered to be the training set. The 2 validation studies were comprised of 8775 and 16,451 women, respectively, and they were carried out between February and September 2015 and between April and December 2016, respectively. Patient‐specific risks of delivery with preeclampsia at <34, <37, and <41+3 weeks’ gestation were calculated using the competing risks model and the performance of screening for preeclampsia by maternal factors alone and the triple test in each of the 3 data sets was assessed. We examined the predictive performance of the model by first, the ability of the model to discriminate between the preeclampsia and no‐preeclampsia groups using the area under the receiver operating characteristic curve and the detection rate at fixed screen‐positive rate of 10%, and second, calibration by measurements of calibration slope and calibration in the large. Results: The detection rate at the screen‐positive rate of 10% of early‐preeclampsia, preterm‐preeclampsia, and all‐preeclampsia was about 90%, 75%, and 50%, respectively, and the results were consistent between the training and 2 validation data sets. The area under the receiver operating characteristic curve was >0.95, >0.90, and >0.80, respectively, demonstrating a very high discrimination between affected and unaffected pregnancies. Similarly, the calibration slopes were very close to 1.0, demonstrating a good agreement between the predicted risks and observed incidence of preeclampsia. In the prediction of early‐preeclampsia and preterm‐preeclampsia, the observed incidence in the training set and 1 of the validation data sets was consistent with the predicted one. In the other validation data set, which was specifically designed for evaluation of the model, the incidence was higher than predicted, presumably because of better ascertainment of outcome. The incidence of all‐preeclampsia was lower than predicted in all 3 data sets because at term many pregnancies deliver for reasons other than preeclampsia, and therefore, pregnancies considered to be at high risk for preeclampsia that deliver for other reasons before they develop preeclampsia can be wrongly considered to be false positives. Conclusion: The competing risks model provides an effective and reproducible method for first‐trimester prediction of early preeclampsia and preterm preeclampsia as long as the various components of screening are carried out by appropriately trained and audited practitioners. Early prediction of preterm preeclampsia is beneficial because treatment of the high‐risk group with aspirin is highly effective in the prevention of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
pROC: an open-source package for R and S+ to analyze and compare ROC curves
Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J.-C., & Müller, M. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-77 · Cited by 13,697
Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia
Rolnik, D. L., Wright, D., Poon, L. C., O’Gorman, N., Syngelaki, A., de Paco Matallana, C., Akolekar, R., Cicero, S., Janga, D., Singh, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704559 · Cited by 2,287
Self-citationO’Gorman, N., Wright, D., Syngelaki, A., Akolekar, R., Wright, A., Poon, L. C., & Nicolaides, K. H. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.08.034 · Cited by 629
Self-citationAspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis
Roberge, S., Bujold, E., & Nicolaides, K. H. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.11.561 · Cited by 628
Self-citationUterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of pre‐eclampsia
Plasencia, W., Maiz, N., Bonino, S., Kaihura, C., & Nicolaides, K. H. (2007) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.5157 · Cited by 425
Self-citation
Cited by
First trimester preeclampsia screening and prediction
Chaemsaithong, P., Sahota, D. S., & Poon, L. C. (2022) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2020.07.020 · Cited by 363
Self-citationSyngelaki, A., Hammami, A., Bower, S., Zidere, V., Akolekar, R., & Nicolaides, K. H. (2019) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.20844 · Cited by 350
Self-citationAdvanced maternal age and adverse pregnancy outcomes
Frick, A. P. (2021) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2020.07.005 · Cited by 304
The competing risk approach for prediction of preeclampsia
Wright, D., Wright, A., & Nicolaides, K. H. (2020) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2019.11.1247 · Cited by 263
Self-citationImpact of new definitions of pre‐eclampsia on incidence and performance of first‐trimester screening
Khan, N., Andrade, W., De Castro, H., Wright, A., Wright, D., & Nicolaides, K. H. (2020) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.21867 · Cited by 59
Self-citation
Metadata
- Authors
- Wright, D., Tan, M. Y., O’Gorman, N., Poon, L. C., Syngelaki, A., Wright, A., & Nicolaides, K. H.
- Venue
- American Journal of Obstetrics and Gynecology
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 220
- Issue
- 2
- Pages
- 199.e1-199.e13
- ISSN
- 0002-9378 (ISSN-L)
- OpenAlex
- W2900915766
- Cited by
- 207
- References
- 5
- FWCI
- 21.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Predictive performance of the competing risk model in screening for preeclampsia. https://app.cochat.ai/papers/10.1016/j.ajog.2018.11.1087
- The paper
- Wright, D., Tan, M. Y., O’Gorman, N., Poon, L. C., Syngelaki, A., Wright, A., & Nicolaides, K. H. (2019). Predictive performance of the competing risk model in screening for preeclampsia. American Journal of Obstetrics and Gynecology. https://doi.org/10.1016/j.ajog.2018.11.1087
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.